JERUSALEM--(BUSINESS WIRE)--Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB http://www.oramed.com), a developer of oral delivery systems, has successfully completed Phase 1B clinical trials of its oral insulin capsule. The Phase 1B trial, which utilized healthy volunteers, was focused on finding the optimal dosage for the formulation of Oramed’s oral insulin product.
Oramed plans to commence Phase 2A clinical trials in Israel in the second quarter of 2008. The Phase 2A study is designed to evaluate the safety and efficacy of Oramed’s oral insulin in Type II Diabetic volunteers. Oramed is simultaneously working on completing the requirements for an IND for Phase 2 FDA approved trials.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is an Israeli-based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimens. Oramed is currently developing an orally ingestible insulin capsule for the treatment of diabetes. The company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information please visit our website at: www.oramed.com.
Forward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company’s ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company’s filings with the Securities and Exchange commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Contact: Oramed Pharmaceuticals, Inc Investor Relations: Erika Moran Public Relations: Lynn Granito, Steve Melfi 212-825-3210 info@oramed.com www.oramed.com
Source: Oramed Pharmaceuticals, Inc.
